Speaker Profile

PHARM.D., Emeritus Faculty, St. Jude Children’s Research Hospital

Biography
Dr. Evans joined St. Jude Children’s Research Hospital in 1972, became faculty in 1976, chaired the Pharmaceutical Sciences Department from 1986-2002, served as Scientific Director & EVP from 2002-2004, and as President and CEO from 2004-2014. For the past 40 years his research has focused on the pharmacodynamics and pharmacogenomics of anticancer agents in children with acute lymphoblastic leukemia. Evans has authored over 400 scientific publications and has received several national awards for his research, the Pediatric Oncology Award from ASCO (with Mary V. Relling), the Remington Medal from APhA, the Oscar B. Hunter Award from ASCPT and the Parker Medal from ACCP. He was elected to the Institute of Medicine of the US National Academy of Sciences (now the US National Academy of Medicine) and the German National Academy of Sciences. He currently chairs the SAB of the Princess Maxima Children’s Cancer Center and serves on the Board of BioSkryb.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB